Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Woodruff

Psychiatry Baltimore, MD Medical Doctor

NPI 1972779023 CMS profile 43801

4419 Falls Road, Suite E, Baltimore, MD 21211

Open in the dashboard

General payments

$4,360

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Woodruff of Baltimore, MD is reported in the CMS Open Payments database as having received $4,360 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $290 9
2024 General $49 2
2023 General $872 30
2022 General $529 23
2021 General $765 38
2020 General $647 27
2019 General $1,208 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Woodruff
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Douglas Woodruff were reported at $290. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Douglas Woodruff Psychiatry median Middle half National median
2019 $1,208 $184 $59–$605 $163
2020 $647 $119 $36–$372 $114
2021 $765 $143 $43–$576 $132
2022 $529 $153 $50–$590 $149
2023 $872 $170 $56–$651 $160
2024 $49 $179 $57–$673 $164
2025 $290 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $538 7 payments
  2. Janssen Pharmaceuticals, Inc $523 10 payments
  3. AbbVie, Inc. $443 20 payments
  4. Sunovion Pharmaceuticals Inc. $434 17 payments
  5. Allergan Inc. $353 10 payments
  6. Supernus Pharmaceuticals, Inc. $312 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $306 15 payments
  8. Adlon Therapeutics L.P. $209 14 payments
  9. Bausch Health US, LLC $149 7 payments
  10. Lundbeck LLC $141 7 payments
  11. Other $954 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,360 155 payments
Products named General payments · program years 2019–2025
  1. LATUDA $434 17 payments
  2. VRAYLAR Neuroscience $429 19 payments
  3. REXULTI $413 6 payments
  4. SPRAVATO $372 8 payments
  5. VRAYLAR Neuroscience $339 10 payments
  6. TRINTELLIX $267 13 payments
  7. ADHANSIA XR $209 14 payments
  8. Qelbree $175 4 payments
  9. WELLBUTRIN $149 7 payments
  10. APLENZIN $149 7 payments
  11. Other $1,450 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

621

Median for Psychiatry & Neurology: 100

Drug cost

$16,915

Median for Psychiatry & Neurology: $2,986

Branded share of claims

20.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dexmethylphenidate Hcl Er Dexmethylphenidate Hcl Brand 12 $4,570
Lurasidone Hcl Generic 12 $2,340
Bupropion Xl Bupropion Hcl Brand 89 $1,906
Atomoxetine Hcl Generic 23 $1,617
Duloxetine Hcl Generic 96 $1,539
Trazodone Hcl Generic 76 $921
Methylphenidate Hcl Generic 17 $591
Oxcarbazepine Generic 16 $577
Buspirone Hcl Generic 55 $500
Alprazolam Generic 22 $395

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record